|
The SITC 2014 Annual Meeting Presentation Archive is supported through a generous contribution from Prometheus Laboratories Inc. Access slide decks and video via the links in the schedule below.
|
 |
| 7:15 am – 8:00 am | Meet-the-Expert Breakfast (Early Career Scientist Event) 0 AMA PRA Category 1 Credits™ (not CME-certified) |
| 7:15 am – 8:00 am | Meet-the-Expert Breakfast (Early Career Scientist Event) 0 AMA PRA Category 1 Credits™ (not CME-certified) |
| 8:00 am – 8:35 am | Presidential Welcome and Update Session .5 AMA PRA Category 1 Credits™ |
| 8:00 am – 8:05 am | Presidential Welcome   Francesco M. Marincola, MD – Sidra Medical and Research Center |
| 8:05 am – 8:20 am | Update Session: U.S. Food and Drug Administration Raj K. Puri, MD, PhD – U.S. Food and Drug Administration |
| 8:20 am – 8:35 am | Update Session: National Cancer Institute William D. Merritt, PhD – National Cancer Institute |
| 8:35 am – 9:25 am | Richard V. Smalley, MD Memorial Lectureship: Cancer as a Disease of the Metaorganism .75 AMA PRA Category 1 Credits™ |
| 8:35 am – 8:40 am | Introduction Francesco M. Marincola, MD – Sidra Medical and Research Center |
| 8:40 am – 9:25 am | Cancer as a Disease of the Metaorganism Giorgio Trinchieri, MD – National Cancer Institute |
| 9:25 am – 12:00 pm | Inflammation, Innate Immunity and Microbiome 2.25 AMA PRA Category 1 Credits Co-Chairs: Marco Colonna, MD – Washington University William J. Murphy, PhD – University of California-Davis |
| 9:25 am – 9:30 am | Session Overview William J. Murphy, PhD – University of California-Davis |
| 9:30 am – 9:55 am | Natural Killer Cell Subsets in Immune Regulation and Tumor Immunity William J. Murphy, PhD – University of California-Davis |
| 9:55 am – 10:20 am | Natural Killer Cells and Innate Lymphoid Cells in Inflammation and Cancer Marco Colonna, MD – Washington University |
| 10:20 am – 10:40 am | Break |
| 10:40 am – 10:55 am | Direct Activation of STING in the Tumor Microenvironment with Synthetic Cyclic Dinucleotide Derivatives Leads to Potent and Systemic Tumor-Specific Immunity Leticia Corrales, PhD – University of Chicago |
| 10:55 am – 11:10 am | Evidence Implicating the Commensal Microbiota in Shaping Anti-Tumor Immunity in Melanoma Ayelet Sivan – University of Chicago |
| 11:10 am – 11:35 am | The Role of the Intestinal Microbiome on GVHD Marcel R.M. van den Brink, MD, PhD – Memorial Sloan-Kettering Cancer Center |
| 11:35 am – 12:00 pm | Roles of the Microbiota in Immunity and Inflammation Yasmine Belkaid, PhD – National Institutes of Health |
| 12:00 pm – 12:30 pm | Late-Breaking Abstract Session 0 AMA PRA Category 1 Credits™ (not CME-certified) |
| 12:00 pm – 12:15 pm | TCR Repertoire Divergence Reflects Microenvironmental Immune Phenotypes in Glioma Jennifer Sims, PhD – Columbia University |
| 12:15 pm – 12:30 pm | Activation of Toll-Like Receptor-2 by Tumor Associated Matrix Metalloproteinase-2 Modulates Dendritic Cell Function Nina Bhardwaj, MD PhD – Icahn School of Medicine at Mt. Sinai |
| 12:30 pm – 2:00 pm | Lunch, Poster Viewing and Exhibits Oral Poster Session 12:50 pm – 1:40 pm |
| 2:00 pm – 4:15 pm | Lung Cancer: Immunology and Immunotherapy 2.25 AMA PRA Category 1 Credits™ Co-Chairs: Roy S. Herbst, MD, PhD – Yale Cancer Center Laurence Zitvogel, MD, PhD – Institute Gustave Roussy |
| 2:00 pm – 2:05 pm | Session Overview Laurence Zitvogel, MD, PhD – Institute Gustave Roussy |
| 2:05 pm – 2:30 pm | Personalizing Lung Cancer Immunotherapy Laurence Zitvogel, MD, PhD – Institute Gustave Roussy |
| 2:30 pm – 2:55 pm | Personalized Immunotherapy for Non-Small Cell Lung Cancer Roy S. Herbst, MD, PhD – Yale Cancer Center |
| 2:55 pm – 3:10 pm | TG4010 Immunotherapy Combined with First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study John Nemunaitis, MD – Mary Crowley Medical Research Center |
| 3:10 pm – 3:25 pm | PD-L1 Expression Correlates with Immune Response in a Phase I Trial of CCL21 Gene Modified Dendritic Cell Therapy in Lung Cancer Jay M. Lee, MD – University of California, Los Angeles |
| 3:25 pm – 3:50 pm | Manipulating Tumor-Immune Cell Interactions in NSCLC Mikael J. Pittet, PhD – Mass General Hospital |
| 3:50 pm – 4:15 pm | PD-1 Immune Checkpoint Blockade: Patient Characteristics and Biomarkers Associated with Response Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| 4:15 pm – 4:45 pm | Break |
| 4:45 pm – 6:10 pm | Concurrent Session — Tumor Microenvironment and Immunosuppression 1.5 AMA PRA Category 1 Credits™ Co-Chairs: Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County Weiping Zou, MD, PhD – University of Michigan |
| 4:45 pm – 4:50 pm | Session Overview Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County |
| 4:50 pm – 5:10 pm | Neutralizing Immune Suppression in the Tumor Microenvironment Suzanne Ostrand-Rosenberg, PhD – University of Maryland Baltimore County |
| 5:10 pm – 5:35 pm | Integrating Immunoregulatory and Vascular Signaling Programs Through Lectin-Glycan Interactions Gabriel A. Rabinovich, PhD – Instituto de Biología y Medicina Experimental (IBYME) |
| 5:35 pm – 5:55 pm | Immune Impact on Cancer Stemness Weiping Zou, MD, PhD – University of Michigan |
| 5:55 pm – 6:10 pm | FcgRIIIA (CD16)-Expressing Monocytes Mediate the Depletion of Tumor-Infiltrating Tregs Via Ipilimumab-Dependent ADCC in Melanoma Patients Emanuela Romano, MD, PhD – University Hospital of Lausanne |
| 4:45 pm – 6:10 pm | Concurrent Session — Immunopotentiation by Radiotherapy: Mechanisms and Opportunities 1.5 AMA PRA Category 1 Credits™ Co-Chairs: Sandra Demaria, MD – New York University Susan Knox, MD, PhD – Stanford University |
| 4:45 pm – 4:50 pm | Session Overview Susan Knox, MD, PhD – Stanford University |
| 4:50 pm – 5:15 pm | New Directions with NKT Cells and Nanoscale Flow Cytometry Jennifer Clare Jones, MD, PhD – National Cancer Institute |
| 5:15 pm – 5:40 pm | Radiotherapy with TGF-β Blockade Jump-Starts Tumor-Specific T Cells and Immune Checkpoint Inhibitors Keep Them Going Sandra Demaria, MD – New York University |
| 5:40 pm – 5:55 pm | The Anti-Tumor Immune Response Generated by Radiation Therapy May be Limited by Tumor Cell Adaptive Resistance and can be Circumvented by PD-L1 Blockade Simon Dovedi, PhD, MSc, BSC – University of Manchester |
| 5:55 pm – 6:10 pm | CD47 Limits Cooperation between Adaptive Tumor Immunity and Radiation Therapy David D. Roberts, PhD – National Cancer Institute |
| 8:00 am – 8:35 am | Welcome and Update Session .5 AMA PRA Category 1 Credits™ |
| 8:00 am – 8:05 am | Welcome and Overview Kim A. Margolin, MD – Stanford University |
| 8:05 am – 8:10 am | Update Session: SITC Biomarkers Task Force Lisa H. Butterfield, PhD – University of Pittsburgh |
| 8:10 am – 8:35 am | Update Session: Cancer Immunotherapy Trials Network Martin A. Cheever, MD – Fred Hutchinson Cancer Research Center |
| 8:35 am – 9:25 am | Keynote Address: Prophylactic Cancer Vaccines - Feasibility and Progress .75 AMA PRA Category 1 Credits™ Olivera J. Finn, PhD – University of Pittsburgh |
| 9:25 am – 12:00 pm | Barriers to Successful Vaccines 2.25 AMA PRA Category 1 Credits™ Co-Chairs: Jonathan L. Bramson, PhD – McMaster University Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne |
| 9:25 am – 9:45 am | Session Overview Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne |
| 9:45 am – 10:05 am | Immunotherapy and the Immunosuppressive Tumor Network Gosse J. Adema, PhD – Radboud University Medical Center |
| 10:05 am – 10:25 am | Antigen-Specific T Cell Responses to Breast Cancer Jill E. Slansky, PhD – University of Colorado |
| 10:25 am – 10:45 am | Break |
| 10:45 am – 11:00 am | Functional Redundancy of PI3K Isoforms in Conventional T Cells Provides a Selective Treg-Targeting Strategy Through Inhibition of PI3K-Delta Isoform Shamim Ahmad, PhD – Georgia Regents University Cancer Center |
| 11:00 am – 11:15 am | Vaccine Targeting HIF1A in Triple Negative Breast Cancer Mary L. Disis, MD, FACP – University of Washington |
| 11:15 am – 11:35 am | Local, Regional, and Systemic Effects of TLR Agonists and IFA as Adjuvants for Peptide Vaccines Craig L. Slingluff, Jr., MD – University of Virginia |
| 11:35 am – 11:55 am | The Use of Peptides in the Therapeutic Vaccination of Cancer Hans-Georg Rammensee, PhD – Universitäet Tüebingen |
| 11:55 am – 12:00 pm | Closing Remarks Daniel E. Speiser, MD – Ludwig Center for Cancer Research of the University of Lausanne |
| 12:00 pm – 12:30 pm | Late-Breaking Abstract Session 0 AMA PRA Category 1 Credits™ (not CME-certified) |
| 12:00 pm – 12:15 pm | DNA Vaccine VGX-3100 with Electroporation Induces Regression of Cervical Intraepithelial Neoplasia 2/3 and Clears HPV Infection with Robust T Cell Responses: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial Laurent M. Humeau, PhD – Inovio Pharmaceuticals |
| 12:15 pm – 12:30 pm | OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells with a Unique T Cell Receptor Repertoire and Synergizes with PDL1 Blockade to Promote Tumor Regression Amy E. Moran, PhD – Earle A. Chiles Cancer Research Institute, Providence Cancer Center |
| 12:30 pm – 2:00 pm | Lunch, Poster Viewing and Exhibits Oral Poster Session 12:50 pm – 1:50 pm |
| 2:00 pm – 3:05 pm | Presidential Session 1.0 AMA PRA Category 1 Credits™ |
| 2:00 pm – 2:05 pm | Introduction Francesco M. Marincola, MD – Sidra Medical and Research Center |
| 2:05 pm – 2:20 pm | Tumor Derived Stress Triggers C/EBPβ Homologous Protein (CHOP) Expression in Myeloid Derived Suppressor Cells (MDSC) and Mediates Immunosuppressive Activity Paul Thevenot, PhD – Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center |
| 2:20 pm – 2:35 pm | Mechanisms of TIGIT-Driven Immune Suppression in Cancer Sema Kurtulus, PhD – Center for Neurologic Diseases Brigham & Women’s Hospital |
| 2:35 pm – 2:50 pm | Melanoma-Intrinsic B-Catenin Signaling Prevents T Cell Infiltration and Anti-Tumor Immunity Stefani Spranger, PhD – University of Chicago |
| 2:50 pm – 3:05 pm | Pre-Clinical Validation of a Humanized Anti-EGFR Variant III Chimeric Antigen Receptor and Phase I Trial of CART-EGFRvIII in Glioblastoma Marcela Maus, MD, PhD – University of Pennsylvania |
| 3:05 pm – 3:25 pm | Immunoscore Update .25 AMA PRA Category 1 Credits™ Bernard A. Fox, PhD – Earle A. Chiles Cancer Research Institute, Providence Cancer Center |
| 3:25 pm – 4:00 pm | Break |
| 4:00 pm – 5:25 pm | Concurrent Session — Coinhibition and Costimulation: Targets and Strategies 1.5 AMA PRA Category 1 Credits™ Co-Chairs: Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center Robert H. Vonderheide, MD, DPhil – University of Pennsylvania |
| 4:00 pm – 4:05 pm | Session Overview Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 4:05 pm – 4:30 pm | OX40 Immunotherapy in Cancer Patients: Immunological Observations and Implications for T Cell Immunotherapy Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 4:30 pm – 4:45 pm | Distinct Immunologic Changes In Vivo Following Combination Versus Individual PD-1 or CTLA-4 Checkpoint Blockade in Human Cancer Kavita Dhodapkar, MD – Yale University |
| 4:45 pm – 5:00 pm | Melanoma Progression is Associated with NK Cell Exhaustion Ines Pires da Silva, MD – New York University Cancer Center |
| 5:00 pm – 5:25 pm | CD40 Agonists in Cancer Immunotherapy Robert H. Vonderheide, MD, DPhil – University of Pennsylvania |
| 4:00 pm – 5:25 pm | Concurrent Session — High Throughput Technologies: Determinants of the Immune Response to Cancer 1.5 AMA PRA Category 1 Credits™ Co-Chairs: Katherine L. Nathanson, MD – University of Pennsylvania Paul F. Robbins, PhD – National Institutes of Health/National Cancer Institute |
| 4:00 pm – 4:05 pm | Session Overview Katherine L. Nathanson, MD – University of Pennsylvania |
| 4:05 pm – 4:30 pm | Use of High Throughput Sequencing to Identify Mutated Tumor Antigens Paul F. Robbins, PhD – National Institutes of Health/National Cancer Institute |
| 4:30 pm – 4:50 pm | Inherited Genetic Response Kevin M. Brown, PhD – National Cancer Institute |
| 4:50 pm – 5:10 pm | Single Cell Functional Analysis Provides Insights into Cancer Patient Responses, including the Development of Resistance, to Cell-Based and Combination Immunotherapies James R. Heath, PhD – California Institute of Technology |
| 5:10 pm – 5:25 pm | T Cell Receptor Diversity Evaluation to Predict Patient Response to Ipilimumab in Metastatic Melanoma Michael Postow, MD – Memorial Sloan-Kettering Cancer Center |
| 8:00 am – 10:15 am | Adoptive Immunotherapy 2.25 AMA PRA Category 1 Credits™ Co-Chairs: Helen E. Heslop, MD – Baylor College of Medicine Per thor Straten, PhD – Centre for Cancer Immune Therapy (CCIT) |
| 8:00 am – 8:05 am | Session Overview Helen E. Heslop, MD – Baylor College of Medicine |
| 8:05 am – 8:30 am | Moving Tumor Infiltrating Lymphocytes and Biomarkers Forward Patrick Hwu, MD – University of Texas, MD Anderson Cancer Center |
| 8:30 am – 8:55 am | Melanoma Therapy using Adoptive Transfer of Expanded Tumor Infiltrating T cells; Prospects and Pitfalls Per thor Straten, PhD – Centre for Cancer Immune Therapy (CCIT) |
| 8:55 am – 9:10 am | Toward Cell Transfer Immunotherapy Against Patient-Specific Mutations in Gastrointestinal Cancers Eric Tran, PhD – National Insitutes of Health/National Cancer Institute |
| 9:10 am – 9:25 am | Modulating Immunometabolism of Tumor Specific CD8 T Cells to Enhance T Cell Based Therapy for Cancer Madhusudhanan Sukumar, PhD – National Cancer Institute |
| 9:25 am – 9:50 am | Enhancing the IQ of CAR T Cells Michael C.V. Jensen, MD – University of Washington |
| 9:50 am – 10:15 am | CAR Therapy: The CD19 Paradigm Michel Sadelain, MD, PhD – Memorial Sloan-Kettering Cancer Center |
| 10:15 am | Annual Meeting Adjourns |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
